Professor Julia Scarisbrick, MBChBhons, FRCP, MD, is a consultant dermatologist leading the Cutaneous Lymphoma Service at University Hospitals Birmingham’s Rare Diseases Centre. She holds a Chair in Immunology and Immunotherapy at the University of Birmingham and trained in London at St Thomas’ and University College London.
She is the current President of the International Society for Cutaneous Lymphomas and serves in leadership roles with the EORTC Cutaneous Lymphoma Taskforce and the UK Photopheresis Society Charity.
A prolific clinical and molecular researcher, Dr. Scarisbrick has:
– Published 150+ peer-reviewed articles
– Authored multiple books
– Led guideline development and clinical studies in cutaneous lymphoma
She co-leads the PROCLIPI Study with Youn Kim (Stanford University), a multicentre international study collecting data on all aspects of CTCL, including treatment and quality of life data. Recently, PROCLIPI published the CLIPI prognostic index, which can precisely stratify advanced MF and SS patients at initial diagnosis into low, intermediate, and high-risk groups for overall survival. She is devoted to improving outcomes for patients with skin lymphoma, including better quality of life and survival.
🏥 University Affiliation, City, Country: University Hospital Birmingham & University of Birmingham
🧪 Area of focus in clinical practice and research: Skin Lymphoma
🔎 Looking forward to in the field of cutaneous lymphomas and at the 6th WCCL: Fostering a forum for scientific and clinical discussions in skin lymphoma
💭 What are you passionate about in medicine or recreationally? Improving outcomes in skin lymphoma
🏆 A short story or academic achievement you are proud of: Fostering collaborations to improve research and better outcomes for patients with skin lymphoma
🌟 Secret to career success: Hardworking, insightful, and affable